ClinicalTrials.gg
CompletedNCT05552274Updated Jul 5, 2024

FTIH of ECC4703 in Healthy Volunteers

An Early Phase 1 interventional study of ECC4703 and Placebo in Non-alcoholic Steatohepatitis (NASH), sponsored by Eccogene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Eccogene · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
186th of 460
75 · median 56
Started
2022
with 37 others
Phase 1
79 of 547
6 open now
Registered
459th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 186th largest by enrollment of the 460 interventional ones that give a count, is one of 38 that started in 2022, is one of 79 in phase 1, and was the 459th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL

Read the detailed description

This study will be conducted in two cohorts of Single Ascending Dose (SAD) with a dose range from 1mg to 400mg and in four cohorts of Multiple Ascending Dose (MAD) with a dose range of 40mg to 160mg to Investigate the Safety, Tolerability, PK, and PD of ECC4703 in Healthy Volunteers and Participants with Treatment Unnecessary LDL-C under 160 mg/dL

03

Conditions studied

  • Non-alcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants of any ethnic origin
  • Age of 18 to 65 years
  • of 18.0 to 32.0 kg/m2
  • Female participants who are , confirmed by FSH test, or surgically sterile, confirmed by medical documentation, or if they are of child bearing potential agree to use at least 1 highly effective method of and 1 additional effective method at the same time, or agree to practice true abstinence
  • Male participants agree to use contraception, or agree to practice true abstinence
  • No findings in physical examination, 12-lead (ECG), vital sign measurements, laboratory tests, or medical/psychiatric history
  • Not taking any medication on a regular basis
  • Able to understand and sign and date

Additional Inclusion Criteria for Part 2 (MAD) Cohorts B2 to B4

  • Fasting LDL-C ≥ 100 mg/dL and ≤ 159 mg/dL at screening
  • Not eligible for lipid-lowering therapy (such as statin) as decided by the qualified clinician at screening based on \<2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease>
  • (HbA1c) ≤ 6.5%.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant including a positive result of pregnancy test, planning to become pregnant, or breastfeeding.
  • History of febrile illness or evidence of active infection within 14 days prior to the first dose of study;
  • Use of any concomitant medication
  • History of drug abuse or alcohol abuse within the past 5 years;
  • Regular use of tobacco, nicotine or tobacco products within the past 6 months of the study ;
  • Unwilling to abstain from alcohol containing products and/or xanthine/caffeine containing products, including any food and beverages, within 48 h prior to the first dose of study drug;
  • Concomitant participation in any study of any nature
  • Blood loss of non-physiological reasons ≥ 200 ml (i.e. trauma, blood collection, blood donation) within 2 months prior to the first dose of study drug, or plan to donate blood during this trial and within 1 month after the last dosing;
  • Abnormal renal function estimated (eGFR) \< 90 mL/min/1.73m2
  • Currently diagnosed type 2 diabetes mellitus (T2DM) or has history of T2DM.
  • Significant allergic reaction to active ingredients or of the study drug.
  • Any abnormal findings in the participant's physical examination, laboratory tests, pregnancy test, urine drug screen, alcohol test, or medical history which in the opinion of the Investigator would prevent the participants from participating in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Placebo comparator
    SAD Cohorts 1 to 2: Participants receiving Placebo

    Participants in each SAD cohort will be randomized to receive placebo

    Drug: Placebo

  • Experimental
    SAD Cohorts 1 to 2: Participants receiving ECC4703

    Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).

    Drug: ECC4703

  • Placebo comparator
    MAD Cohorts 1 to 4: Participants receiving Placebo

    Participants will be randomized to receive a once-daily dose of placebo for 14 days.

    Drug: Placebo

  • Experimental
    MAD Cohorts 1 to 4: Participants receiving ECC4703

    Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.

    Drug: ECC4703

Interventions

  • ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.

  • DrugPlacebo

    Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations

    Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.

    Time frame: SAD: Up to 8 days and MAD: Up to 21 days

Secondary outcomes

  1. Pharmacokinetic Parameters: AUC0-24

    AUC from time 0 to 24 hour dosing interval

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  2. Pharmacokinetic Parameters: AUC0-tlast

    AUC from time 0 to the time of last quantifiable non-zero concentration

    Time frame: SAD: Up to Day 8

  3. Pharmacokinetic Parameters: AUC0-tau

    AUC over a dosing interval from time 0 to time of last quantifiable concentration

    Time frame: MAD: Up to Day 21.

  4. Pharmacokinetic Parameters: AUC0-infinity

    AUC from time 0 extrapolated to infinity

    Time frame: SAD: Up to Day 8

  5. Pharmacokinetic Parameters: Cmax

    Maximum observed plasma concentration

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  6. Pharmacokinetic Parameters: C24

    Observed concentration at 24 hours post dose

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  7. Pharmacokinetic Parameters: Ctau

    Observed concentration at the end of the dosing interval

    Time frame: MAD: Up to Day 21.

  8. Pharmacokinetic Parameters: tmax

    Time of the maximum observed plasma concentration

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  9. Pharmacokinetic Parameters: tlag

    Lag time (time delay between dosing and first observed plasma concentration)

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  10. Pharmacokinetic Parameters: t1/2

    Apparent terminal elimination half-life

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  11. Pharmacokinetic Parameters: Clast

    Last measurable non-zero concentration

    Time frame: SAD: Up to Day 8

  12. Pharmacokinetic Parameters: tlast

    Time of last measurable non-zero concentration

    Time frame: SAD: Up to Day 8

  13. Pharmacokinetic Parameters: CL/F

    Apparent Clearance

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  14. Pharmacodynamic assessment: LDL-C

    Measurement of Low Density Lipoprotein Cholesterol

    Time frame: SAD: Up to Day 8

  15. Pharmacodynamic assessment: HDL-C

    Measurement of High Density Lipoprotein Cholesterol

    Time frame: MAD: Up to Day 21.

  16. Pharmacodynamic assessment: TG

    Measurement of Triglycerides

    Time frame: MAD: Up to Day 21.

  17. Pharmacodynamic assessment: TC

    Measurement of Total Cholesterol

    Time frame: MAD: Up to Day 21.

  18. Pharmacodynamic assessment: LDL

    Measurement of Low Density Lipoprotein

    Time frame: MAD: Up to Day 21.

  19. Pharmacodynamic assessment: VLDL

    Measurement of Very Low Density Lipoprotein

    Time frame: MAD: Up to Day 21.

  20. Pharmacodynamic assessment: ApoB

    Measurement of Apolipoprotein B

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  21. Pharmacodynamic assessment: Lp(a)

    Measurement of Lipoprotein (a)

    Time frame: MAD: Up to Day 21.

  22. Pharmacodynamic assessment: Glucose

    Measurement of Glucose

    Time frame: MAD: Up to Day 21.

  23. Pharmacodynamic assessment: Serum Insulin

    Measurement of Serum Insulin

    Time frame: MAD: Up to Day 21.

  24. Thyroid function assessment: TT3

    Measurement of Total Triiodothyronine

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  25. Thyroid function assessment: FT3

    Measurement of Free Triiodothyronine

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  26. Thyroid function assessment: TT4

    Measurement of Total Thyroxine

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  27. Thyroid function assessment: FT4

    Measurement of Free Thyroxine

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

  28. Thyroid function assessment: TSH

    Measurement of Thyroid Stimulating Hormone

    Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.

07

Study locations

1 site
  • Eccogene Investigational Site
    Las Vegas, Nevada 89113, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2023, 14 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2022
First posted
Sep 23, 2022
StartActual
Aug 16, 2022
Primary completionActual
Oct 26, 2023
CompletionActual
Oct 26, 2023
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05552274
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Aug 16, 2022
Primary completion
Oct 26, 2023
Completion
Oct 26, 2023
Last update
Jul 5, 2024

Study contacts

Eccogene
study director · Eccogene Clinical Trials

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ECC4703

Start the discussion